Generic Name and Formulations:
Idarubicin HCl 20mg/vial; lyophilized pwd for IV infusion after reconstitution.
Various generic manufacturers
- Pediatric Acute Promyelocytic Leukemia: Arsenic Trioxide Consolidation May Improve Outcomes
- Intense-dose Idarubicin Consolidation Prolongs LFS in AML
- Idarubicin + HDAC ± Vorinostat Not Superior to 7+3 in AML
- Leukemia Treatment Regimens: Acute Myeloid Leukemia (AML)
- Emetogenic Potential of Antineoplastic Agents
- Leukemia Treatment Regimens: Acute Lymphoblastic Leukemia (ALL)
Indications for Idarubicin:
Acute myeloid leukemia.
Give by slow IV infusion (over 10–15 mins). 12mg/m2 daily for 3 days (in combination with cytarabine). May give 2nd course if needed; if toxicity develops after 1st course, delay until resolved; reduce dose by 25%. Hepatic and renal impairment: consider reduce dose.
Pre-existing bone marrow suppression. Cardiovascular disease. Thoracic irradiation. Previous anthracycline therapy at high cumulative doses. Renal or hepatic impairment. Monitor CBCs, cardiac, renal and hepatic function prior to and during treatment. Avoid extravasation. Elderly. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Concomitant drugs that suppress cardiac contractility or cardiotoxic drugs (eg, trastuzumab, cyclophosphamide, paclitaxel): not recommended; avoid use for 5 half-lives after discontinuing cardiotoxic drug.
Myelosuppression, GI upset, mucositis, abdominal pain, alopecia, rash, inj site reactions, hepatotoxicity, renal toxicity, cardiotoxicity (eg, CHF, arrhythmias, chest pain, MI, asymptomatic declines in LVEF), hyperuricemia.
Single-dose vials—contact supplier; PFS: Single-dose vials (5mL, 10mL, 20mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Rectal Cancer: Adjuvant Chemotherapy May Improve OS After pCR
- Breast Cancer: Determining the Best Diet for Disease Prevention
- Hormone Therapy for Breast Cancer May Cause Diabetes
- Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers
- Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma